Acrux to study Testosterone MD-Lotion in U.S. phase 2 trial

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Acrux will start a phase 2 clinical trial in the United States following the recent acceptance of an Investigational New Drug application for Testosterone MD-Lotion by the Food and Drug Administration.

The Melbourne, Australia-based drug-delivery company said the aim of the trial, in 40 men with testosterone deficiency, is to demonstrate that once-daily use of the quick-drying lotion maintains testosterone levels within the normal range.

Results of the trial are expected to be available in the second quarter of 2007.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.